Partners United Laboratories International Holdings Ltd (HKG: 3933) and Novo Nordisk (NYSE: NVO) announced positive topline results from a Phase II clinical trial in China evaluating UBT251 for weight management. The long-acting synthetic peptide triple receptor agonist (targeting GLP-1, GIP, and glucagon receptors) demonstrated 19.7% mean weight loss (-17.5 kg) at 24 weeks vs. 2.0% placebo, with statistically significant improvements in metabolic parameters and a favorable safety profile.
Phase II Study Results
Endpoint
UBT251 (6 mg)
Placebo
Clinical Significance
Mean Weight Loss
19.7% (-17.5 kg)
2.0% (-1.6 kg)
17.7 percentage-point advantage; competitive with tirzepatide/zepbound
GLP-1 (satiety) + GIP (potentiation) + GCG (energy expenditure) – potentially superior to dual agonists (tirzepatide) via added metabolic effect
Weight Loss Efficacy
19.7% at 24 weeks approaches tirzepatide SURMOUNT-1 data (20.9% at 72 weeks) – suggests competitive or superior early efficacy
China Market Priority
United Labs leads China development – addresses ~200 million obese adults with localized regulatory and commercial strategy
Novo Nordisk Global Rights
Leverages Wegovy/Ozempic infrastructure for ex-China; UBT251 potential next-gen successor to semaglutide/tirzepatide
Competitive Landscape
Lilly’s retatrutide (triple agonist) Phase III ongoing; UBT251 positions as Novo’s triple agonist response with differentiated PK profile
Development Timeline: China Phase III initiation Q3 2026; global Phase III (Novo) 2027; potential China NDA 2028, U.S./EU 2029
Commercial Potential: Peak China sales RMB 5–8 billion (United Labs); global peak $5+ billion (Novo Nordisk) if approved as best-in-class triple agonist
Forward‑Looking Statements This brief contains forward‑looking statements regarding Phase III trial design, regulatory pathways, and commercial potential for UBT251. Actual results may differ due to durability of weight loss beyond 24 weeks, competitive dynamics with Lilly’s retatrutide, and manufacturing scale-up for peptide triple agonists.-Fineline Info & Tech
By Fineline Cube